A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Completed · Phase 3 · NCT04184622
Conditions: Overweight, Obesity
At a glance
- Research payments reported, 2025
- $69,547
- U.S. investigators named
- 9
- Sites paid
- 10
- Planned or actual enrollment
- 2,539
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2019-12-04; completion 2024-07-06
- Results posted
- Yes
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
From ClinicalTrials.gov, last updated 2025-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $69,547 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Fitz-patrick, M.D. Specialist · Honolulu, HI
- Anuj Bhargava, MD Endocrinology & Diabetes · West Des Moines, IA
- Neil J. Fraser, MD Internal Medicine · Troy, MI
- David G. True, D.O. Rheumatology · Nixa, MO
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- Beal Essink, MD Psychiatry · Salem, OR
- Ramon Ortiz Carrasquillo, M.D. Endocrinology & Diabetes · Manati, PR
- David Fried, MD Internal Medicine · East Greenwich, RI
- Thomas C. Blevins, M.D. Endocrinology & Diabetes · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Manati Medical for Clinical Research $22,516
- David Fitzpatrick MD DBA E West Med Rsrch $15,480
- Velocity Clinical Research Inc $7,200
- Iowa Diabetes and Endocrinology Rsrch Cntr $6,950
- Clinvest Headlands LLC $6,482
- Arcturus Healthcare PLC, Troy Internal $4,000
- Activmed Practices and Research LLC $3,000
- Summit Headlands LLC $2,000
- Texas Diabetes and Endocrinology PA $1,500
- Alliance for Multispecialty Research Lls $419
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.